[
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=51f28d83fdb5a0d37959e91a398049cea5f22ceffc2fecf880eea6b9ee58bdc3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737736380,
      "headline": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "id": 132459575,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=51f28d83fdb5a0d37959e91a398049cea5f22ceffc2fecf880eea6b9ee58bdc3"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?",
    "summary": "We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa’s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur, and investor often referred to as the Canadian Warren […]",
    "url": "https://finnhub.io/api/news?id=4da532727e359ab8018e4acb01cf1de89f84b4e3c28b1392ff50a325412f45c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737720732,
      "headline": "Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?",
      "id": 132505718,
      "image": "https://s.yimg.com/ny/api/res/1.2/krpa0cobX2AdeFb7DJ59pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa’s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur, and investor often referred to as the Canadian Warren […]",
      "url": "https://finnhub.io/api/news?id=4da532727e359ab8018e4acb01cf1de89f84b4e3c28b1392ff50a325412f45c1"
    }
  },
  {
    "ts": null,
    "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., January 24, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial",
    "url": "https://finnhub.io/api/news?id=00616b2fc1756ad089f7420436085184f26036354d8c20a4671f912c70298e8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737719100,
      "headline": "Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma",
      "id": 132505719,
      "image": "https://media.zenfs.com/en/business-wire.com/55d6886e700ef165127b6c2b5729bbb1",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & NUTLEY, N.J., January 24, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial",
      "url": "https://finnhub.io/api/news?id=00616b2fc1756ad089f7420436085184f26036354d8c20a4671f912c70298e8d"
    }
  },
  {
    "ts": null,
    "headline": "Merck: mixed results in esophageal adenocarcinoma",
    "summary": "Merck announces that the phase 3 trial evaluating the combination of Keytruda and Lenvima with chemotherapy for the first-line treatment of patients with HER2-negative advanced gastroesophageal...",
    "url": "https://finnhub.io/api/news?id=426edd81f978255f9e63b510ca8dd184a1208f6d7c427cbceeb9980f0cf1e477",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737706813,
      "headline": "Merck: mixed results in esophageal adenocarcinoma",
      "id": 132454511,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces that the phase 3 trial evaluating the combination of Keytruda and Lenvima with chemotherapy for the first-line treatment of patients with HER2-negative advanced gastroesophageal...",
      "url": "https://finnhub.io/api/news?id=426edd81f978255f9e63b510ca8dd184a1208f6d7c427cbceeb9980f0cf1e477"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study",
    "summary": "By Colin Kellaher Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. ...",
    "url": "https://finnhub.io/api/news?id=5e363d28a02c02059028a0d06918269f8b4fa4ea4eb617a91dbeb209033fdc5b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737704889,
      "headline": "Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study",
      "id": 132454303,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. ...",
      "url": "https://finnhub.io/api/news?id=5e363d28a02c02059028a0d06918269f8b4fa4ea4eb617a91dbeb209033fdc5b"
    }
  }
]